Coherus Biosciences Inc. rose over 30% in US stocks after market hours
六月清晨搅
发表于 2023-12-27 09:40:52
272
0
0
The US stock market of Coherus Biosciences Inc. rose more than 30% after market hours. On December 26th local time, the US Food and Drug Administration (FDA) approved its new cancer drug UDENYCA& Reg; ONBODY. Udenyca is a biologically similar drug to Anjin's cancer drug Neulasta (pegfilgrastim).
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- US chip stocks continue to rise, TSMC gains over 8%
- Bilibili's US stock market rose more than 4% before trading
- Chinese concept stocks and US stocks generally rose before the market opened, with Bilibili rising nearly 4%
- Chinese concept stocks and US stocks generally strengthened before the market opened, and Futu Holdings rose more than 5%
- Bank of America survey: US stock market expected to be the best asset of 2025 after Trump's victory!
- Chinese concept stocks and US stocks mostly rose before the market, with extreme discounts and a nearly 6% increase
- Most US bank stocks rise, with JPMorgan Chase exceeding 1%
- Fuguo Bank's US stock market rose nearly 3% before trading
- RBC Capital raises target prices for multiple US bank stocks
- Micron Technology's US stock fell more than 14% in pre-market trading
